The Effects of Ripasudil in Patients With FED Undergoing Femtosecond Laser Assisted Cataract Surgery

Who May Qualify: 1. Patients with FED who will be listed for cataract surgery as part of standard clinical practice (A cataract will be defined as clouding of the lens that interferes with normal vision). 2. Only patients older than 50 years will be included, as cataracts develops with increasing age. No gender criteria are applied. 3. Ability to provide willing to sign a consent form, and are willing and able to sign a written willing to sign a consent form Form prior to any study-specific procedures. 4. Patients must be willing and able to return for scheduled follow-up examinations for up to 12 months after the surgery. Who Should NOT Join This Trial: 1. Patients who are unable to give consent. 2. An only-functioning eye in a patient who has lost visual potential in the contralateral eye. 3. Diagnosis of clinically relevant eye diseases that may interfere with the aim of the study. 4. History of ripasudil use, as well as other systemic disease such as cardiovascular or renal disease. 5. Patients who have previous allergic reactions to the contents present in Glanatec Ophthalmic solution 0.4% Always talk to your doctor about whether this trial is right for you.